Showing 151–175 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, et al.
…able. We aimed to compare mortality in patients on standard regimens with that of patients on regimens including bedaquiline. Methods In this retrospective cohort study, we analysed patient data from the South African rifampicin-resistant tuberculosis case register (EDRweb), and …
Norbert Ndjeka, Nazir Ismail
…opted both drugs extensively in the modified short and long regimens for rifampicin-resistant or multidrug-resistant tuberculosis. According to the electronic drug-resistant tuberculosis register, as of June 1, 2020, 29 193 individuals in South Africa have received bedaquiline, a…
Mulder C, Rupert S, Setiawan E, Mambetova E, Edo P, et al.
…2 in Nigeria - 57%, 78% and 68% lower than the conventional regimens in the respective countries. A gradual adoption of the BPaL regimen over 5 years would result in an 5-year average national TB service budget reduction of 17% (US$128 780) in XDR-TB treatment-related expenditure…
Fu L, Wang W, Xiong J, Zhang P, Li H, et al.
…ety and effectiveness of two 9-month short-course, all-oral regimens for pre-XDR-TB treatment: Bdq-regimen (consisting of Bdq, linezolid, cycloserine, clofazimine, and pyrazinamide) and SASP-regimen (comprising SASP, linezolid, cycloserine, clofazimine, and pyrazinamide). The pri…
Christoph Lange, Anca Vasiliù, Anna M. Mandalakas
…ial reduction in all-cause mortality compared with standard regimens.4Schnippel K Ndjeka N Maartens G et al.Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.Lancet Respir Med. 2018; 6: 699-706Summary Full …
В. Е. Новиков, Natalia E. Usacheva, T. V. Myakisheva
…tensively drug-resistant (XDR) TB, respectively. Stages and regimens to treat tuberculosis: Chemotherapy of tuberculosis in children is carried out in 2 stages (intensive treatment and continuation of treatment) and includes 5 regimens. Each regimen assumes a certain combination …
Chiara Sepulcri
…ecially in treatment. Multiple short (6-9 months), all-oral regimens are currently available for persons sick with tuberculosis resistant to rifampin/multidrug-resistant (RR/MDR-TB). Some of these regimens are also approved for persons with TB with additional resistance to fluoro…
Chiara Sepulcri
…ecially in treatment. Multiple short (6-9 months), all-oral regimens are currently available for persons sick with tuberculosis resistant to rifampin/multidrug-resistant (RR/MDR-TB). Some of these regimens are also approved for persons with TB with additional resistance to fluoro…
Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E
…easing evidence of the effectiveness and safety of new drug regimens containing bedaquiline for MDR/RR-TB; however, whether they are affordable for high-burden, limited-resource settings is uncertain. Objective Our objective was to determine the incremental cost effectiveness of …
Koushik Mukherjee, Pritam Saha, Kirat Kumar Ganguly, Somjyoti Chakraborty, Swarnali Ghosh, et al.
…ealth threat. Despite advances in diagnostics and treatment regimens, it infects millions annually. It remains a significant global health challenge, particularly due to the appearance of resistance towards anti-tuberculosis drugs (ATD), mainly multidrug-resistant (MDR) and exten…
Анна Старшинова, M. M. Nazarenko, E. N. Belyaeva, D.А. Kudlаy, М. В. Павлова, et al.
…tance patterns and addition of bedaquiline to the treatment regimens: Ia – n = 94 (MDR TB; Bq-) and IIa ‒ n = 80 (XDR TB; Bq-); Ib ‒ n = 22 (MDR TB; Bq+) and IIb ‒ n = 23 (XDR TB; Bq+). Clinical and laboratory parameters of patients, the severity of comorbidity were assessed befo…
Foundation for Innovative New Diagnostics, Switzerland
…month treatment regimen, replacing conventional 18-24 month regimens. The FQs and SLIs are key components of the 6-9 month regimen, and so it is necessary to rule-out resistance to these compounds prior to treating patients with the shorter regimen. For longer MDR-TB treatment re…
Tong E, Wu Q, Chen Y, Liu Z, Zhang M, et al.
…s aim to evaluate the efficacy and safety of BDQ-containing regimens for the treatment of patients with pulmonary TB. Methods PubMed (MEDLINE), Elton B. Stephens Company (EBSCO) database, the Cochrane Register of Controlled Trials, and the China National Knowledge Infrastructure …
Annelies Van Rie, Emilyn Costa Conceição, Felex Ndebele, Felicia Wells, Astrid Paulse, et al.
…s (n=5 [3%]). In the WGS group, 15 different individualised regimens were recommended to 81 participants, and median treatment duration was shortened by 2·6 months. Bacteriological response was similar in both groups with a mean mycobacterial load half-life of 0·30 week…
Wu Y, Zhang Y, Wang Y, Wei J, Wang W, et al.
…t for DR-TB-HIV patients by comparing multiple chemotherapy regimens, to provide a basis for evidence-based practice. Methods We searched three electronic databases (PubMed, Web of Science and Cochrane) for related English studies published since 2010. A random-effect model was u…
Margaretha de Vos, Serej D. Ley, Nabila A. Ismail, Brigitta Derendinger, Anzaan Dippenaar, et al.
… Health Organization has promoted the use of injection free regimens which include new and repurposed drugs: bedaquiline (BDQ), linezolid (LZD) and clofazimine (CFZ). In 2017, South Africa rolled out the inclusion of BDQ in the treatment of all pre-XDR- and XDR-TB cases as well a…
Rafael Laniado-Laborı́n
…endations for programmatic management (the short and longer regimens) and one for operational research (the BPaL regimen).
A Silsarma, AS Iyer, MA Galindo, VV Chavan, Su Khan, et al.
…Group A drugs and form part of shorter and longer BDQ-based regimens under India’s National Tuberculosis (TB) Programme. A systematic review including some data from India on acquired BDQ resistance reports 2.2% phenotypic and 4.4% genotypic resistance in patients treated with BD…
Oelofse S, Esmail A, Diacon AH, Conradie F, Olayanju O, et al.
…daquiline, pretomanid and linezolid [BPaL]) to conventional regimens containing bedaquiline (B, BDQ) and linezolid (L, LZD). METHODS: Six-month post end-of-treatment outcomes were compared between Nix-TB ( n = 109) and 102 prospectively recruited extensively drug-resistant TB pat…
Lorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, Maelenn Gouillou, Muhammad Hammad Ali, et al.
…at this patient population might require longer, reinforced regimens. **FUNDING:** Unitaid, Médecins Sans Frontières, Partners In Health, Interactive Research and Development, Ramón Areces Foundation, the Jung Foundation for Science and Research, Research Foundati…
Yin Mon Thant
…n 75%. With regard to extensively DR-TB (XDR-TB), treatment regimens are based on drug susceptibility results of second-line drugs and includes new drugs (bedaquiline and delamanid).4 Very recently, we have started a transition plan of fully oral treatment for DR-TB. Furthermore,…
A. A. Akzhigitova, T. N. Ignatova, A. К. Konratov, M. В. Теn
Background. Bedaquiline is currently a drug of choice in therapy for extensively and multidrug-resistant tuberculosis. It is indicated for children from a 6-year age and young adults as part of a combination chemotherapy, in compliance with the medical council’s (MC) regulation o…
Enyu Tong, Qian Wu, Yi‐Ming Chen, Zhengwei Liu, Mingwu Zhang, et al.
…aimed to evaluate the efficacy and safety of BDQ-containing regimens for the treatment of pulmonary TB patients. Methods MEDLINE (PubMed), EBSCO, the Cochrane Central Register of Controlled Trials and CNKI (China National Knowledge Infrastructure) were searched to identify eligib…
Bolyskhan Baigabyl, Bolor Rash, Oyunchimeg Adilaa, Yanjindulam Purevsuren, Dorjderem Radnaa
…t test examined the treatment outcomes of BPaL and non-BPaL regimens, the cure rate (BPAL 69%; non-BPaL 29.2%) was statistically significantly different (p=0.04). <b>Conclusion:</b> The treatment success rate of XDR-TB cases was 48.6%. It is three-fold higher with the BPaL regime…
Cynthia Bin Eng Chee, David S.C. Hui
…dence for the efficacy and safety of shorter LTBI treatment regimens (i.e. 12 weeks of weekly rifapentine and isoniazid; 4 months of rifampicin; and 4 weeks of daily rifapentine and isoniazid, the latter in human immunodeficiency virus (HIV)-infected persons) as alternatives to 6…